Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Cardiovascular DiseasesNephropathy

Interventions

DRUG

Tolvaptan

15 mg pr day for 1 day

DRUG

Placebo

1 tablet Unikalk 1 pr day for 1 day

Trial Locations (1)

Safa Therwani, Holstebro

All Listed Sponsors

lead

Regional Hospital Holstebro

OTHER

NCT01638663 - Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA) | Biotech Hunter | Biotech Hunter